- 2026-04-01
- Pakistan journal of pharmaceutical sciences 39(4)
- Li Chen
- Lan Tang
- Weiwei Dong
- Shuhua Zeng
- Sisi Wu
- Hong Ye
Study Design
- Type
- Meta-Analysis
- Sample size
- n = 299
- Population
- patients with endometriosis
- Methods
- systematic review methodology; comprehensive search of databases including PubMed, VIP, CNKI and Wanfang for controlled trials from 2000 to 2025; 12 included trials (1,299 participants)
- Funding
- Unclear
Background
Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity.Objective
This study aimed to investigate the impact of goserelin acetate implants on hormone levels in patients with endometriosis using a systematic review methodology.Methods
A comprehensive search of databases including PubMed, VIP, CNKI and Wanfang was conducted for controlled trials from 2000 to 2025.Results
12 included trials (1,299 participants) showed that goserelin acetate implant treatment significantly improved endometriosis [OR: 5.82, 95% CI (3.20, 10.59), P<0.000001], increased luteinizing hormone [MD: -2.04, 95% CI (-2.26, -1.83), P<0.00001], follicle-stimulating hormone [MD: -2.34, 95% CI (-2.58, -2.10), P<0.00001] and estradiol levels [MD: -1.89, 95% CI (-2.11, -1.66), P<0.00001], while reducing Visual Analog Scale scores [MD: -0.41, 95% CI (-0.48, -0.34), P<0.000001], recurrence rates [OR: 0.15, 95% CI (0.09, 0.24), P<0.00001] and adverse reactions [OR: 0.19, 95% CI (0.06, 0.55), P<0.00001]. The funnel plot exhibited an inverted funnel shape with relative symmetry, indicating no significant publication bias.Conclusion
The study demonstrates that goserelin acetate implants can effectively enhance overall treatment outcomes and regulate hormone levels in endometriosis patients.